ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief [...] Read more »
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset
- Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre–clinical investigational novel compound with broad potential to treat [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »